Arvinas Collaborates with Novartis to Develop and Commercialize ARV-766 for Treating Prostate Cancer
Shots:
- Arvinas & Novartis have signed an exclusive strategic license agreement for the development & commercialization of the former’s ARV-766, Protac AR degrader, globally for prostate cancer as well as an asset purchase agreement for AR-V7’s (preclinical asset) sale to Novartis
- Under the collaboration, Novartis will handle ARV-766’s global clinical development & commercialization plus gain all the rights to research, develop, manufacture & commercialize AR-V7
- Furthermore, Arvinas is entitled to receive $150.0M up front under the asset purchase agreement and an additional ~$1.01B as development, regulatory & commercial milestones plus ARV-766 related tiered royalties through the license agreement
Ref: Arvinas | Image: Arvinas
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
